List of Excipients in Branded Drug GANIRELIX ACETATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	ACETIC ACID
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	MANNITOL
Organon USA Inc	GANIRELIX ACETATE	ganirelix acetate	0052-0301	SODIUM HYDROXIDE

Generic Drugs Containing GANIRELIX ACETATE

Company	Ingredient	NDC	Excipient
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	ACETIC ACID
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	MANNITOL
Amphastar Pharmaceuticals Inc	ganirelix acetate	0548-5001	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in GANIRELIX ACETATE?

# Of NDCs	Excipient
9	ACETIC ACID
9	MANNITOL
9	SODIUM HYDROXIDE

Ganirelix Acetate Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Ganirelix acetate is a sterile, preservative-free, immediate-release injectable used in controlled ovarian stimulation for assisted reproductive technology. Its commercial opportunity is driven less by novel excipients than by reliable sterile manufacturing, syringe performance, cold-chain control, supply continuity, and lower-cost access. The core formulation is relatively simple: ganirelix acetate in an acidic aqueous solution containing mannitol, with acetic acid and sodium hydroxide used for pH adjustment.

The strongest opportunities are generic or private-label supply, prefilled-syringe manufacturing, fertility-clinic distribution, and formulation improvements that reduce adsorption, aggregation, extractables, shipping losses, and device failures without changing the clinical profile.

What is ganirelix acetate and how is it formulated?

Ganirelix acetate is a synthetic gonadotropin-releasing hormone antagonist. It suppresses premature luteinizing hormone surges during controlled ovarian stimulation. In the United States, the marketed dosage form is a subcutaneous injection containing 250 mcg of ganirelix, equivalent to approximately 0.23 mg of ganirelix free base, in 0.5 mL of solution.

The reference formulation is an aqueous, preservative-free solution. Public product labeling identifies the principal excipients as mannitol, acetic acid, sodium hydroxide, and water for injection. The formulation is acidic, with a target pH generally reported in the range of approximately 5.0 to 5.5.[1]

Formulation attribute	Commercial specification
Active ingredient	Ganirelix acetate
Delivered dose	250 mcg ganirelix per 0.5 mL
Route	Subcutaneous
Dosage form	Sterile injectable solution
Preservative	None identified in U.S. labeling
Primary tonicity agent	Mannitol
pH system	Acetic acid and sodium hydroxide
Container	Single-dose syringe or equivalent sterile presentation
Main clinical use	Controlled ovarian stimulation in assisted reproduction

The formulation does not require a complex delivery technology. The technical risk is concentrated in peptide handling, low-dose uniformity, surface adsorption, sterilization strategy, container closure integrity, and compatibility with the syringe and needle system.

What excipients are used in ganirelix acetate injection?

Mannitol is the principal functional excipient. It contributes to tonicity and helps produce an injectable solution that is compatible with subcutaneous administration. Acetic acid and sodium hydroxide establish and adjust the acidic pH. Water for injection is the vehicle.[1]

Mannitol

Mannitol is commercially attractive because it is well understood by regulators, widely available in injectable grades, and compatible with aqueous sterile manufacturing. Its use also reduces the need for a more complicated excipient system.

Potential formulation concerns include:

• Variability in osmolality across manufacturing lots.
• Particulate formation from raw-material impurities.
• Stability effects caused by concentration or pH changes.
• Compatibility with container surfaces and elastomeric components.
• Freeze-thaw and shipping sensitivity.

Mannitol should be controlled through pharmaceutical-grade specifications covering bioburden, endotoxin, particulate matter, identity, assay, and relevant residual impurities.

Acetic acid and sodium hydroxide

These materials are process excipients rather than differentiated commercial ingredients. They establish the target pH and provide batch-to-batch control. The pH window is important because peptide stability, degradation, adsorption, and injection tolerability are all affected by acidity.

A commercial formulation should control:

• Initial pH after compounding.
• pH after terminal sterilization, if applicable.
• pH after accelerated and long-term storage.
• pH after contact with the final syringe and needle.
• Degradation products associated with pH drift.

The use of acetic acid and sodium hydroxide supports a conventional aqueous formulation. It also limits the regulatory value of an excipient substitution because the existing formulation already uses standard, low-risk materials.

Water for injection

Water quality is a critical manufacturing input. Control points include conductivity, total organic carbon, microbial limits, endotoxin, and storage time before compounding. The low dose of ganirelix increases the importance of mixing uniformity and adsorption control relative to the total solution volume.

What excipient strategy is best for ganirelix acetate?

The most defensible strategy is a formulation-preservation strategy rather than an aggressive excipient redesign. A manufacturer seeking an ANDA or a low-risk commercial product should generally prioritize qualitative and quantitative similarity to the reference product.

Strategy 1: Match the reference formulation

A reference-matched formulation minimizes regulatory and clinical risk. The target profile should include:

• The same active concentration.
• The same nominal fill volume.
• The same or closely comparable mannitol level.
• The same acidic pH range.
• No preservative.
• Comparable osmolality.
• Comparable syringe and needle configuration.
• Comparable visible and subvisible particulate profile.

For a conventional injectable solution, changes in inactive ingredients may create additional FDA review. The FDA’s Inactive Ingredient Database is relevant to excipient precedent and route-specific exposure, but it does not eliminate the need to establish product quality and compatibility.[2]

Strategy 2: Improve container compatibility

Ganirelix acetate is supplied at a low concentration. Low-dose peptide products can be sensitive to adsorption on glass, silicone oil, elastomers, and other contact materials. Commercial development should evaluate:

• Siliconized versus silicone-free syringes.
• Cyclic olefin polymer or cyclic olefin copolymer components.
• Tungsten residues in prefilled syringes.
• Needle adhesive and lubricant compatibility.
• Plunger stopper extractables and leachables.
• Headspace oxygen and nitrogen overlay.
• Surface adsorption over shelf life.
• Dose recovery at the end of storage.

A silicone-free or low-silicone syringe may provide a differentiated quality proposition if it reduces visible particles, aggregation, or dose loss. The value is likely to be greater in premium fertility-clinic channels than in highly price-sensitive generic contracts.

Strategy 3: Preserve the simple aqueous presentation

Lyophilization, a dual-chamber syringe, or a reconstitution kit would add manufacturing and administration complexity. These approaches are not commercially attractive for a product already supplied as a small-volume ready-to-use injection unless they materially improve stability or enable a new distribution model.

Potential benefits of a lyophilized product include improved thermal stability and broader logistics options. The disadvantages include:

• Higher fill-finish cost.
• Reconstitution error risk.
• Additional device components.
• More complex extractables and leachables testing.
• New labeling and human-factors requirements.
• Potential need for a 505(b)(2) pathway rather than a straightforward ANDA.

Strategy 4: Avoid preservatives

A multidose preserved presentation could reduce packaging cost but would depart from the established single-dose, preservative-free profile. Preservatives may create local tolerability concerns and require additional safety and compatibility work. A multidose product would also need a robust in-use stability package.

The stronger commercial path is a single-dose, ready-to-use presentation with efficient filling and packaging.

What patents protect ganirelix acetate and its formulation?

The original ganirelix compound and GnRH-antagonist patent families are generally old relative to the current generic market. The principal commercial risk is therefore not a single unexpired compound patent but the combined effect of formulation, manufacturing, device, regulatory, and supply-chain barriers.

Public FDA records, including the Orange Book, should be used to determine whether a specific reference product has current listed patents or regulatory exclusivity.[3] Ganirelix acetate is a small-molecule product, so biosimilar exclusivity does not apply. A generic applicant would normally evaluate the product under the ANDA framework if the proposed product can meet the relevant sameness and equivalence requirements.

Formulation patents

Potentially relevant formulation claim categories include:

• Aqueous ganirelix acetate solutions.
• Defined pH ranges.
• Mannitol-containing formulations.
• Specific concentration and fill-volume combinations.
• Stability-improving excipient systems.
• Low-particulate or low-adsorption presentations.
• Prefilled syringe configurations.
• Container closure systems.

The practical strength of these claims depends on their expiration status, written description, enablement, prosecution history, and whether they are listed in the Orange Book. A broad claim to a simple aqueous formulation may face substantial validity and obviousness pressure if the formulation uses conventional excipients at predictable concentrations.

Method-of-use patents

Method-of-use claims could cover administration during controlled ovarian stimulation, timing relative to follicle development, or use with gonadotropins and assisted reproductive protocols. Such claims may be commercially relevant even when compound protection has expired.

A generic applicant may address method-of-use patents through a Paragraph IV certification or a section viii statement, depending on the scope and labeling implications. Carve-out analysis is central because fertility treatment protocols can be described in overlapping clinical language.

Manufacturing and device patents

Manufacturing claims may cover:

• Peptide purification.
• Salt formation.
• Sterile filtration.
• Low-binding contact surfaces.
• Filling into prefilled syringes.
• Needle-shield or plunger arrangements.
• Inspection and particulate control.

These patents can create commercial friction even when they do not prevent an ANDA approval. A generic manufacturer can often use a non-infringing process or alternative device, but process changes may increase development cost and technical risk.

When does ganirelix acetate lose exclusivity?

Ganirelix acetate has no biosimilar exclusivity issue because it is a synthetic small molecule. The relevant barriers are small-molecule patents, FDA regulatory exclusivity, and any current listed patents for the applicable reference product.

Exclusivity category	Relevance to ganirelix acetate
New chemical entity exclusivity	Historical issue; the original product is long past the relevant period
Orphan-drug exclusivity	Not generally the primary market barrier
Pediatric exclusivity	Must be checked against the applicable FDA record
Formulation patents	Potentially relevant, but claim scope and expiration control
Method-of-use patents	Potentially relevant to fertility-treatment labeling
Biosimilar exclusivity	Not applicable
ANDA exclusivity	May apply to an individual first generic applicant
Device patents	May affect presentation, not necessarily market entry

The commercial market should be treated as largely exposed to generic competition unless a current, enforceable patent or regulatory exclusivity period is identified for the specific reference product and indication.

What is the Orange Book status of ganirelix acetate?

The FDA Orange Book is the controlling source for approved drug products, therapeutic equivalence ratings, listed patents, and exclusivity information.[3] Ganirelix acetate should be assessed by product name, active ingredient, dosage form, strength, and reference-listed drug status.

For commercial diligence, the relevant checks are:

1. Whether the reference product is listed as the reference-listed drug.
2. Whether the product has an AB-rated generic.
3. Whether any patents are listed under the reference product.
4. Whether a patent delisting or 30-month stay issue exists.
5. Whether any unexpired exclusivity blocks approval or launch.
6. Whether multiple manufacturers have approved or pending products.

An Orange Book entry alone does not resolve all infringement risk. Unlisted patents, device patents, process patents, contractual restrictions, and foreign rights remain separate issues.

Which companies are challenging or competing with ganirelix acetate?

The competitive field has three layers: branded ganirelix products, generic ganirelix products, and alternative GnRH antagonists.

Direct ganirelix competition

Direct competitors include products marketed under ganirelix acetate or ganirelix injection names. The product has historically been associated with Organon’s Orgalutran outside the United States and Ferring’s Fyremadel in the United States. Generic manufacturers can compete through lower pricing, distributor contracts, and fertility-clinic supply agreements.

Pharmacologic competition

The main pharmacologic competitor is cetrorelix acetate, another GnRH antagonist used in controlled ovarian stimulation. Cetrorelix is marketed as Cetrotide and has generic competition in certain markets.

Product	Active ingredient	Main use	Commercial distinction
Fyremadel or generic ganirelix	Ganirelix acetate	Prevention of premature LH surge	Small-volume ready-to-use injection
Orgalutran	Ganirelix acetate	Same therapeutic class	Major non-U.S. branded presentation
Cetrotide or generic cetrorelix	Cetrorelix acetate	Prevention of premature LH surge	Direct pharmacologic substitute
Leuprolide protocols	Leuprolide acetate	Pituitary suppression	Different mechanism and treatment protocol

Competition is determined by clinic protocol, physician preference, payer coverage, availability, patient training, and total IVF-cycle cost. A product that is technically interchangeable may still face switching barriers in fertility clinics.

What formulation patents could create commercial opportunities?

The strongest opportunities are narrow, product-quality patents rather than broad composition claims.

Low-adsorption syringe systems

A patent or design-control program could focus on a ganirelix prefilled syringe that improves delivered-dose recovery and reduces peptide interaction with the barrel, lubricant, stopper, or needle. Claims might cover the combination of:

• Ganirelix acetate solution.
• Defined pH and osmolality.
• Low-silicone or silicone-free barrel.
• Specific elastomer formulation.
• Specified storage period.
• Controlled subvisible particle limits.

The commercial benefit would be strongest if supported by comparative stability and dose-recovery data.

Low-temperature or thermal-stability formulations

A formulation with improved stability under temperature excursions could reduce product loss in fertility-clinic distribution. Potential approaches include:

• Optimized buffer capacity.
• Surface-interaction control.
• Reduced oxygen exposure.
• Improved syringe materials.
• Alternative mannitol concentration.
• Lyophilization for selected markets.

The regulatory burden rises as the formulation departs from the reference product. A meaningful stability advantage is required to justify the additional development work.

Device-led differentiation

The product can be differentiated through:

• Needle-shield improvements.
• Reduced injection force.
• User-friendly prefilled syringes.
• Low dead volume.
• Tamper-evident packaging.
• Barcode and serialization integration.
• Packaging optimized for IVF cycle kits.

Device protection may be more durable commercially than a simple excipient patent if it is linked to manufacturing know-how and clinic procurement contracts.

What FDA regulatory pathway applies to a new ganirelix product?

A conventional generic ganirelix acetate injection would generally target an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence, along with compliance with current good manufacturing practice requirements.[4]

Key development components include:

• Same active ingredient and strength.
• Same dosage form and route.
• Comparable inactive-ingredient profile.
• Sterility and endotoxin control.
• Particulate and extractables testing.
• Container closure integrity.
• Stability data.
• Device performance, if supplied in a prefilled syringe.
• Labeling consistent with the reference product.

A materially different formulation, new delivery system, or new indication could require a 505(b)(2) application. That route may provide more formulation freedom but increases clinical, regulatory, and patent exposure.

What generic entry risks exist for ganirelix acetate?

Generic entry risk is high where the reference product has no effective current patent or exclusivity barrier. The main risks for an entrant are operational rather than pharmacological.

Risk	Impact	Mitigation
Sterile fill-finish failure	High	Qualified contract manufacturing and process validation
Peptide adsorption	Medium to high	Contact-material screening and dose-recovery testing
Particulate formation	High	Low-silicone components and inspection controls
Supply interruption	High	Dual-source active ingredient and critical components
Device incompatibility	Medium	Integrated combination-product development
Price compression	High	Efficient packaging and clinic/distributor contracts
Small market size	Medium	Multi-country registration and contract supply
Paragraph IV litigation	Medium	Early patent and claim-chart analysis
Clinical switching resistance	Medium	Training, support, and reliable availability

Because the injection is used during time-sensitive IVF cycles, shortages can materially affect clinic purchasing. Supply reliability can support a premium over the lowest generic price.

How strong is the patent estate for ganirelix acetate?

The core patent estate is likely weak as a barrier to ordinary generic entry because the active ingredient and basic therapeutic use are mature. The strongest remaining protection, where available, is more likely to involve:

• Specific delivery devices.
• Narrow formulation ranges.
• Manufacturing processes.
• Packaging systems.
• Method-of-use limitations.
• Country-specific patents.

A simple mannitol-acetic acid-water formulation is difficult to protect broadly unless the patent claims a specific and non-obvious stability or compatibility result. Patent strength should be scored claim by claim rather than by counting patent families.

Estate component	Likely barrier strength
Core molecule	Low if expired
Basic aqueous injection	Low to medium
Narrow pH or excipient range	Medium
Prefilled syringe system	Medium
Manufacturing process	Medium, dependent on detectability
Method of use	Medium, dependent on label and enforcement
Trade secrets in fill-finish	Medium to high operational value
Biosimilar protection	Not applicable

What licensing and partnering opportunities exist?

Ganirelix acetate is suitable for licensing models that combine an established active pharmaceutical ingredient source with regional sterile fill-finish and fertility-channel distribution.

Potential structures include:

Regional generic licensing

A manufacturer with an approved or near-approved product can license rights by territory to fertility-focused pharmaceutical companies. The license value depends on:

• Regulatory approval status.
• Local reference-product requirements.
• Manufacturing capacity.
• Pricing controls.
• IVF procedure volumes.
• Distribution access.

Contract manufacturing

Specialized sterile manufacturers can offer formulation, filling, packaging, and serialization. The most attractive model is a dual-source arrangement that protects against shortages and reduces dependence on a single facility.

Device partnerships

A syringe or autoinjector company could partner with a ganirelix manufacturer to develop a differentiated presentation. The commercial case is strongest where the device reduces injection force, handling time, or administration errors.

IVF portfolio bundling

Ganirelix can be bundled with gonadotropins, progesterone, hCG, or other fertility products through clinic contracts. Portfolio bundling may improve formulary access but can increase antitrust, pricing, and channel-management complexity.

What revenue exposure does ganirelix acetate create?

Ganirelix is a cycle-linked product. Demand depends on the number of controlled ovarian stimulation cycles, protocol selection, dosing duration, and geographic market access. Each treatment cycle typically uses several injections, so volume is tied to IVF activity rather than chronic prescription prevalence.

Commercial exposure is concentrated in:

• Fertility clinics.
• Specialty pharmacies.
• Hospital outpatient pharmacies.
• IVF distributors.
• Public and private reproductive-health programs.

The product has modest differentiation as a molecule but high supply sensitivity. A manufacturer with dependable availability can win contracts even without a novel excipient system. Margin pressure will increase as multiple generic suppliers enter, particularly where payers and clinics treat ganirelix and cetrorelix as interchangeable protocol options.

What is the commercial outlook for ganirelix acetate?

The best near-term opportunity is a cost-efficient, preservative-free, prefilled or ready-to-use sterile product with strong supply reliability. A novel excipient system is unlikely to create a large premium unless it produces measurable improvements in stability, dose recovery, particulate control, or device usability.

Commercial priorities should be:

1. Secure a reliable source of pharmaceutical-grade ganirelix acetate.
2. Use a reference-matched aqueous formulation for the initial product.
3. Validate syringe and elastomer compatibility early.
4. Build a dual-source fill-finish network.
5. Target fertility-clinic and specialty-distributor contracts.
6. Develop a differentiated low-silicone or low-dead-volume presentation as a follow-on product.
7. Evaluate the United States, European Union, Japan, and high-volume IVF markets as separate regulatory and pricing opportunities.
8. Monitor FDA Orange Book listings and Paragraph IV activity before launch.

Key Takeaways

• Ganirelix acetate injection uses a simple preservative-free aqueous formulation based on mannitol, acetic acid, sodium hydroxide, and water for injection.
• The strongest initial development strategy is reference matching, not broad excipient innovation.
• Container compatibility, low adsorption, particulate control, and syringe performance are the main technical opportunities.
• Ganirelix is a small molecule, so biosimilar risk does not apply.
• Generic entry risk is high where no unexpired patent or regulatory exclusivity blocks approval.
• The commercial market is linked to IVF cycle volume and fertility-clinic purchasing.
• Cetrorelix acetate is the principal pharmacologic competitor.
• Device, packaging, and manufacturing patents may offer more practical value than broad excipient claims.
• Supply continuity can support commercial differentiation after generic entry.
• A 505(j) ANDA is the likely route for a conventional equivalent injection; materially different formulations may require 505(b)(2).

FAQs

Can mannitol be replaced in a ganirelix acetate generic?

Yes, but replacement can increase regulatory and development risk. The alternative must support appropriate tonicity, stability, compatibility, and injectable safety. A reference-matched mannitol formulation is generally the lower-risk path.

Is a preservative-free ganirelix formulation commercially necessary?

It is not necessarily required for every product design, but it is commercially advantageous because the established presentation is single-dose and preservative-free. A preserved multidose product would need additional tolerability, in-use stability, and packaging justification.

Can ganirelix acetate be sold in an autoinjector?

Potentially. An autoinjector could improve usability, but it would create combination-product, human-factors, dose-delivery, and device-validation requirements. The product volume and subcutaneous route are technically compatible with device-based delivery.

Does ganirelix acetate require refrigerated distribution?

Storage requirements depend on the approved product and stability package. A commercial developer should design stability studies around labeled storage, temperature excursions, syringe compatibility, and transport conditions. A formulation with demonstrated excursion tolerance could reduce distribution losses.

Is cetrorelix acetate a direct substitute for ganirelix acetate?

It is a pharmacologic competitor, but it is not automatically substitutable at the pharmacy level. Protocol selection, dosing schedules, product labeling, payer rules, and physician preference determine practical interchangeability.

References

1. U.S. Food and Drug Administration. (2024). Fyremadel (ganirelix acetate injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.
5. European Medicines Agency. (2024). Orgalutran: EPAR product information.